IgniteData, an expert in clinical trial data automation, has closed its Series A funding round led by FCA Venture Partners, with participation from SpringTide and Oncology Ventures. This investment will help IgniteData grow its global research site network and enhance its Archer platform, which streamlines clinical trial data transfer from EHR to EDC systems and data warehouses.
The funding highlights strong industry support for IgniteData’s real-time automated data transfer between providers and pharmaceutical sponsors. The company is already operating in leading cancer centers and expanding into community hospitals worldwide.
FCA Venture Partners, based in Nashville, brings not only capital but also strategic connections within healthcare delivery networks. Returning investors SpringTide and Oncology Ventures increased their support, showing confidence in IgniteData’s progress.
Plans include expanding the site network, international deployments, and new product modules to access more clinical data. IgniteData is leveraging large language models and intelligent data mapping to boost trial speed, data quality, and collaboration.
Upcoming milestones involve board expansion, partnerships, and product innovation, keeping IgniteData at the forefront of clinical trial modernization.
KEY QUOTES:
“This round is about scale. The demand for smarter, faster clinical trials is exploding. We’ve already validated product-market fit and built deep integrations with top-tier sponsors and sites. This investment enables us to extend our footprint, unlock new data domains, and deliver on the industry’s need for intelligent data solutions at a global scale.”
Zach Taft, CEO of IgniteData
“IgniteData represents a compelling opportunity to invest in a company that has established itself as the leader in this fast-evolving space. Their adoption by the world’s top cancer centers and leading pharmaceutical sponsors demonstrates the value of their solution. IgniteData has developed a scalable data automation platform that delivers measurable results. We look forward to supporting their continued growth, global expansion, and the continued advancement of their transformative technology.”
Matt King, Managing Partner at FCA Venture Partners
“We backed IgniteData early because we believed in their vision to revolutionize clinical trials through intelligent automation — and to truly reduce burden on clinical sites while accelerating research. Today, we’re doubling down because they’ve exceeded expectations. They’re not just leading — they’re winning, and they’re transforming how sites and sponsors work together.”
Ryan Morley, Partner at SpringTide
